Caredx (CDNA) closed at $87.41 on October 30, 2026, up 22.2% from the previous close, on volume of 3,383,792 shares (30-day average 1,372,520).
Data as of October 30, 2026.
30-Oct-2026
Investors pivot to safety as low-volatility stocks back in spotlight
Seeking Alpha News (Fri, 30-Oct 10:19 AM ET)
CareDx soars as Q3 revenue hits $139M and 2026 guidance jumps to $520M–$530M
Market Chameleon (Fri, 30-Oct 6:02 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Fri, 30-Oct 6:46 AM ET)
Biggest stock movers Friday: Crypto stocks, INTC, RDDT, and more
Seeking Alpha News (Fri, 30-Oct 5:08 AM ET)
Biggest stock movers Friday: Crypto stocks, INTC, RDDT and more
Seeking Alpha News (Fri, 30-Oct 5:08 AM ET)
CareDx lifts 2026 outlook after strong Q3 results
TipRanks (Thu, 29-Oct 4:55 PM ET)
CareDx Non-GAAP EPS of $0.70 beats by $0.44, revenue of $139M beats by $17.04M
Seeking Alpha News (Thu, 29-Oct 4:04 PM ET)
CareDx Announces Third Quarter 2026 Financial Results
Business Wire (Thu, 29-Oct 4:01 PM ET)
CareDx’s MERIT Trial: New Data-Driven Approach to Heart Transplant Rejection
TipRanks (Thu, 29-Oct 12:31 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 29-Oct 10:00 AM ET)
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Caredx trades on the NASDAQ stock market under the symbol CDNA.
As of October 30, 2026, CDNA stock price climbed to $87.41 with 3,383,792 million shares trading.
CDNA has a beta of 0.46, meaning it tends to be less sensitive to market movements. CDNA has a correlation of 0.01 to the broad based SPY ETF.
CDNA has a market cap of $4.52 billion. This is considered a Mid Cap stock.
Last quarter Caredx reported $139 million in Revenue and $.70 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.48.
In the last 3 years, CDNA traded as high as $90.87 and as low as $4.92.
The top ETF exchange traded funds that CDNA belongs to (by Net Assets): VTI, XBI, IWM, ARKG, VXF.
CDNA has outperformed the market in the last year with a price return of +512.1% while the SPY ETF gained +11.0%. CDNA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +146.9% and +31.1%, respectively, while the SPY returned +3.9% and -2.1%, respectively.
CDNA support price is $68.72 and resistance is $74.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDNA shares will trade within this expected range on the day.